Jean-francois F. Chatal

Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care.

Journal: Cancers

Published: February 10, 2025

Alphatherapy, the new impetus to targeted radionuclide therapy?

Journal: European journal of nuclear medicine and molecular imaging

Published: April 27, 2018

ImmunoPET to help stratify patients for targeted therapies and to improve drug development.

Journal: European journal of nuclear medicine and molecular imaging

Published: June 01, 2016

Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: October 15, 2015

Story of Rubidium-82 and Advantages for Myocardial Perfusion PET Imaging.

Journal: Frontiers in medicine

Published: June 16, 2015

The long history of the International Research Group in Immuno-Scintigraphy and Therapy (IRIST).

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: April 14, 2015

Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: March 11, 2015

¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: December 16, 2013

Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care.

Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care.

Alphatherapy, the new impetus to targeted radionuclide therapy?

Alphatherapy, the new impetus to targeted radionuclide therapy?

ImmunoPET to help stratify patients for targeted therapies and to improve drug development.

ImmunoPET to help stratify patients for targeted therapies and to improve drug development.

Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?

Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?

Story of Rubidium-82 and Advantages for Myocardial Perfusion PET Imaging.

Story of Rubidium-82 and Advantages for Myocardial Perfusion PET Imaging.

The long history of the International Research Group in Immuno-Scintigraphy and Therapy (IRIST).

The long history of the International Research Group in Immuno-Scintigraphy and Therapy (IRIST).

Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?

Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?

Tumor immunotargeting using innovative radionuclides.

Tumor immunotargeting using innovative radionuclides.

A pretargeting system for tumor PET imaging and radioimmunotherapy.

A pretargeting system for tumor PET imaging and radioimmunotherapy.

¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.

¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.

Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?

Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?

Improvement of radioimmunotherapy using pretargeting.

Improvement of radioimmunotherapy using pretargeting.